Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539526 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 106
- Enrollment target
NCT00539526 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 106 participants.
The verdict
NCT00539526, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
Interventions
- DRUG Bimatoprost 0.03%
- DRUG travoprost 0.004%
- DRUG latanoprost 0.005% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539526
The ClinicalTrials.gov registry entry for NCT00539526 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bimatoprost 0.03% is the first listed.
NCT00539526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539526 about?
NCT00539526 is a clinical study titled "Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues". This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
What is the current status of trial NCT00539526?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2007-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00539526?
The interventions under investigation include: Bimatoprost 0.03% (DRUG), travoprost 0.004% (DRUG), latanoprost 0.005% eye drops (DRUG).
Who is sponsoring clinical trial NCT00539526?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.